Navigation Links
Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
Date:6/15/2010

n">12:00-1:00 PM.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com.

Safe Harbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's fi
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
4. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
5. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
6. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
7. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
9. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
10. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
11. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Pacific Biomarkers and ... solutions for developers of biosimilars at the 2013 ... Sheraton San Diego Hotel and Marina ... will have the opportunity to speak with company representatives ... Paths That Cross" on May 21 from 1-2 p.m. ...
(Date:5/20/2013)... 20, 2013 Cempra, Inc. (Nasdaq: CEMP), ... antibiotics to meet critical medical needs in the ... presented data at the American Thoracic Society International ... demonstrating the antibacterial and enhanced immunomodulatory activity ... 2 clinical trial in outpatients with community acquired ...
(Date:5/20/2013)... Pittsburgh, PA (PRWEB) May 20, 2013 ... the Allegheny General Hospital (AGH) Cardiovascular Institute ... of coronary artery disease (CAD) over the ... procedures such as balloon angioplasty and coronary artery stent ... will once again play a prominent role in the ...
(Date:5/20/2013)... May 20, 2013 On 25-28 July, ... – in Paris - the beautiful city of lights. ... "Personalized Medicine is revolutionizing the medical world. Understanding and ... is the hallmark of this transformation. Much of the ... from the epidemiologic studies of large cohorts that do ...
Breaking Biology Technology:Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2
... (Nasdaq:,INSM), today announced that it has been awarded ... (MDA). The grant is expected to cover a,substantial ... 24-week,Phase 3 enabling trial in patients with Myotonic ... biopharmaceutical company with extensive,expertise in biologics and orphan ...
... Filed With the FDA for the Fourth Genmab Antibody ... the Company,s Collaboration with Roche., COPENHAGEN, December 12 ... New Drug application (IND) for a,Genmab antibody developed under ... FDA by Roche. Genentech and Roche are collaborating on,development ...
... Toronto Stock Exchange Symbol: MS, EDMONTON, Dec. ... leading developer in the treatment of multiple sclerosis ... Board (DSMB) has,reviewed data from the Company,s on-going ... for the treatment of secondary progressive MS and,recommended ...
Cached Biology Technology:Insmed Awarded $2.1 Million by Muscular Dystrophy Association 2Insmed Awarded $2.1 Million by Muscular Dystrophy Association 3Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2
(Date:5/17/2013)... for Experimental Biology (FASEB) released a new analysis ... highlighting the devastating impact of sequestration on the nation,s ... a May 15th Senate Appropriations Committee hearing featuring NIH ... $1.6 billion cut the agency sustained in FY 2013 ... the scientific community." , According to data from ...
(Date:5/16/2013)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for The Society for Developmental Biology (SDB) ... 16-20, 2013. These awards are meant to promote ... underrepresented groups into the mainstream of the basic ... young scientists at the SDB 2013 Annual Meeting. ...
(Date:5/16/2013)... Injectable nanoparticles developed at MIT may someday eliminate ... to constantly monitor their blood-sugar levels and inject ... to sense glucose levels in the body and ... thereby replacing the function of pancreatic islet cells, ... diabetes. Ultimately, this type of system could ensure ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... post doctoral fellow Virginie Mieulet, in the Faculty of Medicine ... is so vital in fighting infection. , They have discovered ... body know that it,s being attacked by an infection. , ... could have implications for the millions of people in third ...
... Trypanosomes are parasites responsible for many human and ... parasites cause, African sleeping sickness, results from the bite ... at risk in 36 sub-Saharan countries. The recent 1998-2001 ... of Congo and Uganda killed tens of thousands of ...
... A team led by Massachusetts General Hospital (MGH) scientists ... accurately isolating neutrophils the most abundant type of ... accomplishment that could provide information essential to better understanding ... system, described in a Nature Medicine paper ...
Cached Biology News:New research shows how disease-causing parasite gets around human innate immunity 2New research shows how disease-causing parasite gets around human innate immunity 3New research shows how disease-causing parasite gets around human innate immunity 4Microfluidic device allows collection, analysis of hard-to-handle immune cells 2
... This immunoaffinity purified antibody detects an ... molecular mass of ErbB-2 phosphorylated at tyrosine ... product has been cross adsorbed against the ... detect the non-phosphorylated form of the protein. ...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
Biology Products: